ArticleCureus2025
Non-ablative 1927 nm Fractional Thulium Laser With Bimatoprost to Treat a Hypopigmented Burn Scar.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypopigmented scars present a cosmetic and psychological burden, especially in patients of darker skin types. Novel strategies to restore pigment are limited and often ineffective. A 48-year-old woman presented with a complaint of hypopigmented burn scars on both arms. Two months prior, the patient received an intense pulsed light (IPL) treatment at a medical spa. At her initial consultation, she was prescribed Ruxolitinib (a Janus Kinase (JAK) inhibitor) 1.5% (Opzelura) cream to use each morning and tacrolimus 0.1% ointment (a calcineurin inhibitor) to use every night. After six weeks of applying topicals, she then received two non-ablative 1927 nm fractional thulium laser treatments with bimatoprost 0.03% ophthalmic solution (Latisse) six weeks apart while continuing her topical routine at home. After 18 weeks of treatment, most of the patient's pigment had returned. The laser created micro-channels for enhanced topical absorption, while the topical agents reduced inflammation and promoted melanogenesis. This combination offers a promising, non-invasive treatment for hypopigmented burn scars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.